On Thursday, October 7, 2021, Life Sciences BC held a webinar on radiopharmaceuticals, a new class of drugs that is emerging to expand the spectrum of treatments for cancer. These drugs deliver radiation directly and specifically to cancer cells. and they contain radioactive isotopes and can be used as both diagnostic and therapeutic agents.
Targeting radiation therapy at the cellular level has the potential to reduce the risk of both short-term and long-term side effects of treatment, while proving effective at killing even the small clusters of cancer cells throughout the body.
Reduced side effects and precision delivery are driving the interest and high growth in this new generation of radiopharmaceuticals. A number of new therapies are emerging, including using lutetium-177 to treat prostate and neuroendocrine cancers. The global market for radiopharmaceuticals was estimated at $6.1 billion in 2019, and is projected to reach $12.6 billion by 2027.
The Blakes Breakfast Speaking Series is our longest-standing event series and one of our most popular. These breakfasts include presentations by local, national, and multinational life science companies and typically attract a cross-section of approximately 75 of our life sciences community members. The Breakfast Speaking Series is proudly presented by Blake, Cassels & Graydon LLP.
- Noël Brown, Managing Director & Head of U.S. Biotechnology Investment Banking, RBC Capital Markets
- Kathryn Hayashi, President & CEO, TRIUMF Innovations
- Dr. Lana Janes, Venture Partner at adMare BioInnovations, Interim CEO at Abdera Therapeutics
- Cody Shirriff, CEO & Founder, Serenity Bioworks